In preclinical studies, selinexor increased p53 localization in the nucleus and synergized with PIs to induce significant cytotoxicity in PI‐resistant MM cells10 and in a MM xenograft mouse model.17 The gene discussed is TP53; the disease is Miyoshi myopathy.